Engaging mFARS Scale to Monitor Friedreich Ataxia Progression

An expert in Friedreich's ataxia evaluates the mFARS (modified Friedreich's Ataxia Rating Scale) measurement tool, highlighting its advantages and limitations, while also exploring alternative assessment methods for tracking disease progression.

EP: 1.Friedreich Ataxia: Addressing Treatment Objectives and Comorbidities

EP: 2.Guidelines & FDA Approval of Novel Friedreich Ataxia Therapy

Now Viewing

EP: 3.Engaging mFARS Scale to Monitor Friedreich Ataxia Progression

EP: 4.Managing Adverse Events in Novel Friedreich’s Ataxia Therapy

EP: 5.Examining Trial Data on Omaveloxolone Efficacy

EP: 6.Promising Therapy Approaches for Advanced Friedreich Ataxia

• The mFARS measurement tool is frequently reserved for clinical trials due to its time-consuming nature. What alternative tool do you employ to monitor disease progression, and have you observed any shifts in these metrics following the approval of omaveloxolone?
• What is the clinical value of omaveloxolone in patients with wheelchair dependence?

Related Videos

Related Content

Advertisement

September 10th 2024

Bacterial STIs in Men Living With HIV Associated With Drug Use in Sexual Context

Julia Bonavitacola

Drug use, participation in exchange sex, and depressive symptoms were all found to be associated with bacterial sexually transmitted infections (STIs) in sexual minority men living with HIV.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

September 9th 2024

New Hope for Rare but Challenging HER2 Mutations in NSCLC

Christina Mattina

Data presented in the second Presidential Symposium at the 2024 World Conference on Lung Cancer showed encouraging responses to novel agents among patients with HER2-mutated non–small cell lung cancer (NSCLC).

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

September 9th 2024

Spouses, Relatives of Patients With GU Cancer Face Elevated Cardiovascular, Psychological Comorbidity Risks

Brooke McCormick

Spouses and first-degree relatives of patients with genitourinary (GU) cancers face increased risks of developing cardiovascular and psychological comorbidities, particularly within the first year of diagnosis.

September 9th 2024

There Is Room for Improvement in Immunotherapy: Dr Siow Ming Lee

Kyle Munz

Siow Ming Lee, PhD, FRCP, University College London Hospitals, discusses essential advancements necessary for improving immunotherapy outcomes in special patient subgroups with lung cancer.

Related Content

Advertisement

September 10th 2024

Bacterial STIs in Men Living With HIV Associated With Drug Use in Sexual Context

Julia Bonavitacola

Drug use, participation in exchange sex, and depressive symptoms were all found to be associated with bacterial sexually transmitted infections (STIs) in sexual minority men living with HIV.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

September 9th 2024

New Hope for Rare but Challenging HER2 Mutations in NSCLC

Christina Mattina

Data presented in the second Presidential Symposium at the 2024 World Conference on Lung Cancer showed encouraging responses to novel agents among patients with HER2-mutated non–small cell lung cancer (NSCLC).

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

September 9th 2024

Spouses, Relatives of Patients With GU Cancer Face Elevated Cardiovascular, Psychological Comorbidity Risks

Brooke McCormick

Spouses and first-degree relatives of patients with genitourinary (GU) cancers face increased risks of developing cardiovascular and psychological comorbidities, particularly within the first year of diagnosis.

September 9th 2024

There Is Room for Improvement in Immunotherapy: Dr Siow Ming Lee

Kyle Munz

Siow Ming Lee, PhD, FRCP, University College London Hospitals, discusses essential advancements necessary for improving immunotherapy outcomes in special patient subgroups with lung cancer.